reboxetine has been researched along with nisoxetine in 8 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (nisoxetine) | Trials (nisoxetine) | Recent Studies (post-2010) (nisoxetine) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 316 | 2 | 62 |
| Protein | Taxonomy | reboxetine (IC50) | nisoxetine (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.0079 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.0079 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.4 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0131 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0083 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.8628 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A | 1 |
| Biegon, A; Ding, YS; Fowler, J; Lin, KS; Logan, J; Pareto, D | 1 |
| Benveniste, H; Carter, P; Ding, YS; Lin, KS; Logan, J | 1 |
| Arango, V; Kumar, JSD; Majo, VJ; Mann, JJ; Milak, MS; Parsey, RV; Prabhakaran, J; Severance, AJ; Simpson, NR; Van Heertum, RL | 1 |
| Fujibayashi, Y; Kanegawa, N; Kawashima, H; Kiyono, Y; Kuge, Y; Saji, H; Sugita, T; Ueda, M | 1 |
| Babbs, AJ; Chatfield, RE; Krülle, TM; McCormack, JG; Provost, D; Thomas, GH; Widdowson, PS | 1 |
| Carson, RE; Ding, YS; Fan, X; Gallezot, JD; Lin, SF; Mulnix, T; Sherwin, RS; Weinzimmer, D; Yeckel, CW | 1 |
| Gouaux, E; Penmatsa, A; Wang, KH | 1 |
8 other study(ies) available for reboxetine and nisoxetine
| Article | Year |
|---|---|
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters | 2003 |
Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region.
Topics: Animals; Brain; Carbon Radioisotopes; Fluorine Radioisotopes; Fluoxetine; Ligands; Morpholines; Papio; Positron-Emission Tomography; Raclopride; Reboxetine | 2005 |
Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisox
Topics: Adrenergic Uptake Inhibitors; Animals; Autoradiography; Benzopyrans; Binding, Competitive; Brain; Brain Chemistry; Brain Mapping; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Evaluation Studies as Topic; Fluorine Radioisotopes; Fluoxetine; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Maprotiline; Mice; Morpholines; Nordefrin; Norepinephrine Plasma Membrane Transport Proteins; Papio; Positron-Emission Tomography; Protein Binding; Radioligand Assay; Reboxetine; Symporters; Time Factors; Tissue Distribution | 2005 |
In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter.
Topics: Adrenergic Uptake Inhibitors; Animals; Carbon Radioisotopes; Diagnostic Imaging; Fluoxetine; Image Processing, Computer-Assisted; Kinetics; Ligands; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Papio; Positron-Emission Tomography; Reboxetine; Sensitivity and Specificity; Serotonin Plasma Membrane Transport Proteins; Time Factors | 2007 |
Evaluation of radioiodinated (2S,alphaS)-2-(alpha-(2-iodophenoxy)benzyl)morpholine as a radioligand for imaging of norepinephrine transporter in the heart.
Topics: Animals; Binding, Competitive; Desipramine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluoxetine; Heart; Iodine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Morpholines; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperazines; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Rats; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tissue Distribution | 2008 |
5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Appetite Depressants; Blood Pressure; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Fluoxetine; Heart Rate; Male; Models, Animal; Morpholines; Norepinephrine; Pyrimidines; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Triazines | 2009 |
Ex vivo and in vivo evaluation of the norepinephrine transporter ligand [11C]MRB for brown adipose tissue imaging.
Topics: Adipose Tissue, Brown; Animals; Fluoxetine; Ligands; Male; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Reboxetine; Wakefulness | 2012 |
X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine.
Topics: Animals; Antidepressive Agents; Crystallography, X-Ray; Dopamine Plasma Membrane Transport Proteins; Drosophila melanogaster; Drosophila Proteins; Fluoxetine; Morpholines; Protein Binding; Reboxetine | 2015 |